Short-term preoperative IL-2 immunotherapy in operable pancreatic cancer: A randomized study

Hepato-Gastroenterology

Volumn 56, Issue 91-92, 2009, Pages 861-865

  Uggeri, Franco ^a   Caprotti, Roberto ^a   De Grate, Luca ^a   Crippa, Stefano ^a   Nobili, Cinzia ^a   Penati, Cristina ^a   Romano, Fabrizio ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Immunodeficiency; Immunotherapy; Interleukin 2; Lymphocytopenia; Pancreatic cancer

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FEVER; ERYTHEMA; FEMALE; HELPER CELL; HUMAN; HYPOTENSION; LYMPHADENECTOMY; LYMPHOCYTE COUNT; MALE; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PREOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERLEUKIN-2; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; RECOMBINANT PROTEINS;

EID: 67651219577     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Monson JRT, Ramsden C, Guillou PJ: Decreased IL-2 production in patients with gastrointestinal cancer. Br J Surg 1986; 73:483-486. (Pubitemid 16092851)
2. Lissoni P, Barni S, Rovelli F, Tancini G: Lower survival in metastatic cancer patients with reduced interleukin-2 blood concentrations: preliminary report. Oncology 1991; 48:125-127.
3. Zorn U, Dallmann I, Grosse J, Kirchner H, Poliwoda H, Atzpodien J: Soluble interleukin-2 receptors abrogate IL-2-induced activation of peripheral mononuclear cells. Cytokine 1994; 6:358-364. (Pubitemid 24263879)
4. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A: IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146:3444-3451.
5. Fischer JR, Schindel M, Stein N, Stein N, Lahm H, Gallati H, Kramer PH, Drings P: Selective suppression of cytokine secretion in patients with small-cell lung cancer. Ann Oncol 1995; 6:921-926.
6. Maltoni M, Pirovano M, Nanni O, Marinari M, Indelli M, Gramazio A, Terzoli E, Luzzani M, De Marinis F, Caraceni A, Labianca R: Biological indices predictive of survival in 519 Italian terminally ill cancer patients. J.Pain Symptom Manage 1997; 13:1-9.
7. Yamaguchi K, Maeda S, Kitamura K: Prognostic factors in colorectal carcinoma: significance of peripheral T lymphocytes. Int Surg 1989; 74:232-239. (Pubitemid 20053082)
8. Slade MS, Simmons RL, Yunis E, Greegerg LJ: Immunodepression after surgery in normal patients. Surgery 1975; 78:363-372.
9. Lundy J, Ford CM: Surgery, trauma and immune suppression. Evolving the mechanism Ann Surg 1983; 197:434-438.
10. Brivio F, Fumagalli L, Franciosi C, Uggeri F, Brivio O, Castoldi M, Rescaldani R: La risposta immunitaria da trauma chirurgico e sua relazione con la prognosi nei pazienti operati per carcinoma del colon-retto. Chirurgia 1998; 11:379-381. (Pubitemid 29197055)
11. Brivio F, Lissoni P, Tisi E, Erba L, Barni S, Tancini G, Rescaldani R, Alderi G, Nociti V: Effects of a preoperative therapy with interleukin-2 on surgery-induced lymphocytopenia in cancer patients. Oncology 1992; 49:215-218.
12. Nichols PH, Ramsden CW, Ward U, Sedman PC, Primrose JN: Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer. Cancer Res 1992; 52:5765-5769.
13. Cerea K, Romano F, Ferrari Bravo A, Motta V, Uggeri F, Brivio F, Fumagalli L, Uggeri F: Phase IB study on prevention of surgery-induced immunodeficiency with preoperative administration of low-dose subcutaneous interleukin-2 in gastric cancer patients. J Surg Oncol 2001; 78:32-37. (Pubitemid 32802834)
14. Lissoni P, Barni S, Ardizzpoia A, Olivini G, Brivio F, Tisi E, Tancini G, Characiejus D, Kothari L: Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration:potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin. J Biol Regul Homeost Agents 1993; 7:121-125. (Pubitemid 24118977)
15. Konrad MW, Hemstreet G, Hersh EM: Pharmcokinetics of recombinant interleukin-2 in humans. Cancer Res 1990; 50:2009-2017.
16. Castelino DJ, McNair P, Kay TW: Lymphocytopenia in a hospital population-what does it signify? Aust NZ J Med 1997; 27:170-174.
17. Hiram CP, Wellhausen RS, Regan MP: Systemic study of host defense processes in baldy injured patients. Ann Surg 1986; 204:282-299. (Pubitemid 16014248)
18. Weese JL, Ottery FD, Emoto SE: Do operation facilitate tumor growth? An experimental model in rats. Surgery 1986; 100:273-277. (Pubitemid 16070860)
19. Riddle PR, Berenbaum MC: Postoperative depression of the lymphocyte response to phytohemagglutinin. Lancet 1967; 1:746-748.
20. Toft P, Svendensen P, Tonnesen E, Rasmussen JW: Redistribution of lymphocytes after cortisol administration. APMIS 1992; 100:154-158.
21. Toft P, Svendesen P, Tonnesen E, Rasmussen JW, Christensen NJ: Redistribution of lymphocytes after major surgical stress. Acta Anaesthesiologica Scan 1993; 37:245-249. (Pubitemid 23199793)
22. Oka M, Hirazawa K, Yamamoto K, Izuka N, Hazama S, Suzuki T, Kobayashi N: Induction of Fas-mediated apoptosis on circulating lymphocytes by surgical stress. Annals of Surgery 1996; 4:434-440. (Pubitemid 26115281)
23. Fuchs D, Hausen A, Hiber C: Urinaty neoprotein in the diagnosis and follow-up of human neoplasia, a biochemical parameter to detect cell mediated immune-response. Tumor Biol 1984; 5:199-209. (Pubitemid 15225746)
24. Steger CG, Pierce WC, Figlin R, Czernin J, Kaboo R, Dekernion JB, Okama T, Belldegun A: Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo. Clin Immunol Immunopathol 1994; 72:237-247.
25. Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, Montero F, Joyeux I, Pouillort P, Fridman WH : Serum Interleukin-6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 1994; 69:911-913. (Pubitemid 24140673)
26. Masotti A, Morandini G, Ortolani R, Fumagalli L: Phase-II randomized study of pre-operative IL-2 administration in operable NSCLC. Lung Cancer 1998; 20:191-202. (Pubitemid 28356836)
27. Geertsen PF, Gore ME, Negrier S, Tourani JM, von der Maaseh: Safety and efficacy of subcutaneous and continous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma. Br J Cancer 2004; 90:1156-1162. (Pubitemid 38496807)
28. Bocci V, Pessina GP, Nicoletti C: The lymphatic route. VII. Distribution of recombinant human interleukin-2 in rabbit plasma and lymph. J Biol Regul Homeost Agents 1990; 4:25-29. (Pubitemid 20292311)